A- A A+

The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users. 

Shram, M.J., Henningfield, J.E., Apseloff, G. et al. 

Transl Psychiatry 13, 192 (2023). doi.org/10.1038/s41398-023-02473-8


Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder. 

Wang L, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. 

J Clin Psychol. 2023 Aug 16. doi: 10.1002/jclp.23582. Epub ahead of print. PMID: 37584532.


The effect of sustainable low-dose sildenafil and cognitive-behavioral training on sexual function in methadone-treated men-a randomized controlled trial. 

Tavakolifard N, Amini Z. 

J Addict Dis. 2023 Jul 18:1-8. doi: 10.1080/10550887.2023.2186763. Epub ahead of print. PMID: 37462341.



Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies

Degenhardt, Louisa et al.

The Lancet Psychiatry, Volume 0, Issue 0 



Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety.

Saloner, B, Whitley, P, Dawson, E, Passik, S, Gordon, AJ, Stein, BD. 

Addiction. 2023. doi.org/10.1111/add.16180


Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder: A Randomized Clinical Trial. 

Belcher AM, Cole TO, Massey E, Billing AS, Wagner M, Wooten W, Epstein DH, Hoag SW, Wickwire EM, Greenblatt AD, Colloca L, Rotrosen J, Magder L, Weintraub E, Wish ED, Kaptchuk TJ. 

JAMA Netw Open. 2023 Apr 3;6(4):e237099. doi: 10.1001/jamanetworkopen.2023.7099. PMID: 37043203; PMCID: PMC10099063.


Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder. 

Thakrar AP, Pytell JD, Stoller KB, Walters V, Weiss RD, Chander G. 

J Subst Use Addict Treat. 2023 Apr 23;150:209055. doi: 10.1016/j.josat.2023.209055. Epub ahead of print. PMID: 37088398.


Influence of CYP2B6 Genotype on Methadone Dosage in Patients from the Methadone Maintenance Treatment (MMT) Program in Pereira, Colombia. 

Isaza C, Castaño-Ramírez OM, Vélez JP, Henao J, Beltrán-Angarita L, Sepúlveda-Arias JC. 

Life (Basel). 2023 Apr 18;13(4):1038. doi: 10.3390/life13041038. PMID: 37109567; PMCID: PMC10145268.


Methadone maintenance treatment alters couplings of default mode and salience networks in individuals with heroin use disorder: A longitudinal self-controlled resting-state fMRI study. 

Chen J, Li Y, Wang S, Li W, Liu Y, Jin L, Li Z, Zhu J, Wang F, Liu W, Xue J, Shi H, Wang W, Jin C, Li Q. 

Front Psychiatry. 2023 Apr 17;14:1132407. doi: 10.3389/fpsyt.2023.1132407. PMID: 37139328; PMCID: PMC10149709.



Huo, Samantha et al.

Journal of Emergency Medicine, Volume 64, Issue 3, 391 - 396 


Safety of rapid inpatient methadone initiation protocol: A retrospective cohort study.

Racha S, Patel SM, Bou Harfouch LT, Berger O, Buresh ME. 

J Subst Use Addict Treat. 2023 Mar 15;148:209004. doi: 10.1016/j.josat.2023.209004. Epub ahead of print. PMID: 36931605.



Risk of motor vehicle collisions after methadone use: A systematic review and meta-analysis. 

Tsai TY, Tu SY, Wu CC, Ho PS, Tung CL, Tsai JH, Yang YH, Wu KF, Chuang HY. 

Drug Alcohol Depend. 2023 Mar 11;246:109832. doi: 10.1016/j.drugalcdep.2023.109832. Epub ahead of print. PMID: 36933540.


Crystal methamphetamine use and methadone maintenance treatment dissatisfaction: A prospective cohort study in Vancouver, Canada. 

Cui Z, Hayashi K, Bach P, Milloy MJ, Kerr T. 

J Subst Use Addict Treat. 2023 Jan 18:208956. doi: 10.1016/j.josat.2023.208956. Epub ahead of print. PMID: 36804867.



Analysis of Methadone and EDDP in Addicted Patients under Methadone Substitution Treatment: Comparison of Urine and Plasma as Biological Samples. 

Ciucă Anghel DM, Ciobanu AM, Guțu CM, Stan M, Tudor G, Baconi DL. GC-MS 

Molecules. 2022 Nov 30;27(23):8360. doi: 10.3390/molecules27238360. PMID: 36500452; PMCID: PMC9739625.


Psychosocial combined with methadone maintenance treatments versus methadone maintenance treatments alone for treatment of opioid use disorder: A meta-analysis. 

Liu C, Li Y. 

J Addict Dis. 2023 Jan 6:1-10. doi: 10.1080/10550887.2022.2158664. Epub ahead of print. PMID: 36607171.



CYP genetic polymorphism, pharmacokinetics of methadone, and the biggest risks

Jovanovic M., Bozovic N., Rancic N., Pjevac A., Rascanin S., and Stojkovic M.

Heroin Addiction and Related Clinical Problems, Published Ahead of Print, December 3, 2022


The effect of a methadone-initiated memory reconsolidation updating procedure in opioid use disorder: A translational study. 

Yue JL, Yuan K, Bao YP, Meng SQ, Shi L, Fang Q, Guo XJ, Cao L, Sun YK, Lu TS, Zeng N, Yan W, Han Y, Sun J, Shi J, Kosten TR, Xue YX, Wu P, Lu L. 

EBioMedicine. 2022 Nov;85:104283. doi: 10.1016/j.ebiom.2022.104283. Epub 2022 Sep 28. PMID: 36182773; PMCID: PMC9525804.


Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response. 

Xie X, Gu J, Zhuang D, Zhou Y, Chen X, Shen W, Li L, Liu Y, Xu W, Hong Q, Xu Z, Chen W, Zhou W, Liu H. 

J Clin Lab Anal. 2022 Nov;36(11):e24750. doi: 10.1002/jcla.24750. Epub 2022 Oct 28. PMID: 36305091; PMCID: PMC9701885.


The therapeutic effect of N-acetylcysteine as an add-on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double-blind, placebo-controlled clinical trial. 

Padoei F, Mamsharifi P, Hazegh P, Boroumand H, Ostadmohammady F, Abbaszadeh-Mashkani S, Banafshe HR, Matini AH, Ghaderi A, Dehkohneh SG. 

Brain Behav. 2022 Nov 30:e2823. doi: 10.1002/brb3.2823. Epub ahead of print. PMID: 36448959.


Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. 

Kharasch ED, Regina KJ, Blood J, Friedel C. 

Anesthesiology. 2015 Nov;123(5):1142-53. doi: 10.1097/ALN.0000000000000867. PMID: 26389554; PMCID: PMC4667947.


Methadone-induced hypoglycemia: A case report. 

Malboosbaf R, Hatami N, Maghsoomi Z. 

J Diabetes Investig. 2022 Oct 6. doi: 10.1111/jdi.13919. Epub ahead of print. PMID: 36201002.


Decision tree model based prediction of the efficacy of acupuncture in methadone maintenance treatment. 

Dong Y, Fan B, Yan E, Chen R, Wei X, Zhan J, Zeng J, Wen H, Lu L. 

Front Neurol. 2022 Oct 6;13:956255. doi: 10.3389/fneur.2022.956255. PMID: 36277917; PMCID: PMC9582273.


Neurological Manifestations of Chronic Methadone Maintenance Therapy: A Case Report and Literature Review. 

Gasimova U, Afzal KM, Acharya AB. 

Cureus. 2022 Sep 24;14(9):e29534. doi: 10.7759/cureus.29534. PMID: 36312663; PMCID: PMC9595224.


Transitioning From High-dose Methadone to Buprenorphine Using a Microdosing Approach: Unique Considerations at ASAM Level 3 Facilities. 

Anderson C, Cooley R, Patil D. 

J Addict Med. 2022 Sep 26. doi: 10.1097/ADM.0000000000001085. Epub ahead of print. PMID: 36161824.



2-Minute Neuroscience: Methadone (Video)

Methadone is commonly used to treat opioid use disorder even though its pharmacological action is very similar to that of other opioids like morphine. In this video, I discuss the qualities that make methadone an effective treatment for opioid addiction, along with how it acts to reduce the risks associated with opioid abuse. (Neuroscientifically Challenged, 07.06.2019, Video, 01:58)


REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats. 

Henningfield J, Gauvin D, Bifari F, Fant R, Shram M, Buchhalter A, Ashworth J, Lanier R, Pappagallo M, Inturrisi C, Folli F, Traversa S, Manfredi PL. 

Sci Rep. 2022 Jul 6;12(1):11389. doi: 10.1038/s41598-022-15055-3. PMID: 35794162; PMCID: PMC9259683.


Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.

Sadek J, Saunders J. 

BMC Psychiatry. 2022 Jul 30;22(1):516. doi: 10.1186/s12888-022-04175-9. PMID: 35908052; PMCID: PMC9338516.


Sex differences in weight gain during medication-based treatment for opioid use disorder: A meta-analysis and retrospective analysis of clinical trial data. 

Manza P, Kroll D, McPherson KL, Johnson A, Dennis E, Hu L, Tai B, Volkow ND. 

Drug Alcohol Depend. 2022 Jul 16;238:109575. doi: 10.1016/j.drugalcdep.2022.109575. Epub ahead of print. PMID: 35868182.



A Review of Novel Methods To Support The Transition From Methadone and Other Full Agonist Opioids To Buprenorphine/Naloxone Sublingual In Both Community and Acute Care Settings,

Ghosh, Sumantra Monty MD, MSc, FRCPC, ISAM1; Klaire, Sukhpreet MD, CCFP2; Tanguay, Robert MD, FRCPC, ISAM3; Manek, Mandy MD, CCFP4; Azar, Pouya MD, FRCPC, ISAM5

The Canadian Journal of Addiction: December 2019 - Volume 10 - Issue 4 - p 41-50, doi: 10.1097/CXA.0000000000000072


Treatment Choices: Methadone

Exchange Supplies, UK. Third edition. oD